Inflammatory Response after Different Ablation Strategies for Paroxysmal Atrial Fibrillation
Keywords:paroxysmal atrial fibrillation; catheter ablation; inflammation; recurrence of atrial fibrillation
Background: Catheter ablation for atrial fibrillation (AF) has been gaining popularity; however, the trend of inflammatory response markers in patients treated with different catheter ablation strategies over time and their predictability of AF recurrence remain unknown.
Methods: A total of 210 patients with AF were enrolled and grouped according to surgical mode as follows: freeze group, RF group, and freeze3D group. The subjects were tested for related indexes before and after surgery. To determine AF recurrence during follow up, 24-h ambulatory electrocardiography was performed at two, three, six, and 12 months after surgery.
Results: The inflammation indexes of the three groups peaked between one and three days after surgery but fell at different time points (P < .05). The recurrence rate of paroxysmal atrial fibrillation (PAF) was positively correlated with the increase in the percentage of white blood cells and neutrophils after surgery (P < .05).
Conclusions: The postoperative inflammation indices peaked and fell at different time points after different catheter ablation methods. In addition, the recurrence rate of AF in patients treated with freeze3D is lower.
Afari N, Mostoufi S, Noonan C, et al. 2011. C-Reactive Protein and Pain Sensitivity: Findings from Female Twins. Ann Behav Med 42:277-283.
An K, Zhu J, Ma N, Tang M, Mei J. 2018. Predictive risk factors for recurrent atrial fibrillation after modified endoscopic ablation: A 2-year follow-up. Clin Cardiol 41:372-377.
Antolič B, Pernat A, Cvijić M, Žižek D, Jan M, Šinkovec M. 2016. Radiofrequency catheter ablation versus balloon cryoablation of atrial fibrillation: markers of myocardial damage, inflammation, and thrombogenesis. Wien Klin Wochenschr 128:480-487.
Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. 1997. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96:3542-3548.
Chierchia GB, de Asmundis C, Müller-Burri SA, et al. 2009. Early recovery of pulmonary vein conduction after cryoballoon ablation for paroxysmal atrial fibrillation: a prospective study. Europace 11:445-449.
da Silva RM. 2017. Influence of inflammation and atherosclerosis in atrial fibrillation. Curr Atheroscler Rep 19:2.
Deneke T, Khargi K, Müller KM, et al. 2005. Histopathology of intraoperatively induced linear radiofrequency ablation lesions in patients with chronic atrial fibrillation. Eur Heart J 26:1797-1803.
Gerstenfeld EP, Callans DJ, Dixit S, Zado E, Marchlinski FE. 2003. Incidence and location of focal atrial fibrillation triggers in patients undergoing repeat pulmonary vein isolation: implications for ablation strategies. J Cardiovasc Electrophysiol 14:685-690.
Jin LL, You L, Xie RQ. 2018. Value of cystatin C in predicting atrial fibrillation recurrence after radiofrequency catheter ablation. J Geriatr Cardiol 15:725-731.
Korantzopoulos P, Kolettis TM, Kountouris E, Siogas K, Goudevenos JA. 2005. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? Int J Clin Pract 59:881-885.
Krijthe BP, Kunst A, Benjamin EJ, et al. 2013. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 34:2746-2751.
Kuck KH, Fürnkranz A, Chun KR, et al. 2016. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J 37:2858-2865.
Lim HS, Schultz C, Dang J, et al. 2014. Time Course of Inflammation, Myocardial Injury, and Prothrombotic Response After Radiofrequency Catheter Ablation for Atrial Fibrillation. Circ Arrhythm Electrophysiol 7:83-89.
Mesas CE, Augello G, Lang CC, et al. 2006. Electroanatomic remodeling of the left atrium in patients undergoing repeat pulmonary vein ablation: mechanistic insights and implications for ablation. J Cardiovase Electrophysiol 17:1279-1285.
Mukherjee R. 2016. Fire in the "hall"! Myocardial inflammation and recurrence of atrial fibrillation. J Thorac Cardiovasc Surg 151:1683-1685.
Nanthakumar K, Plumb VJ, Epstein AE, Veenhuyzen GD, Link D, Kay GN. 2004. Resumption of electrical conduction in previously isolated pulmonary veins: rationale for a different strategy? Circulation 109:1226-1229.
Richter B, Gwechenberger M, Socas A, et al. 2012. Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin Res Cardiol 101:217-225.
Rienstra M, Sun JX, Magnani JW, et al. 2012. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). Am J Cardiol 109:533-537.
Schmidt M, Marschang H, Clifford S, et al. 2012. Trends in inflammatory biomarkers during atrial fibrillation ablation across different catheter ablation strategies. Int J Cardiol 158:33-38.
Shao M, Shang L, Shi J, et al. 2018. The safety and efficacy of second-generation cryoballoon ablation plus catheter ablation for persistent atrial fibrillation: A systematic review and meta-analysis. PLoS One 13:e0206362.
Stein A, Wessling G, Deisenhofer I, et al. 2008. Systemic inflammatory changes after pulmonary vein radiofrequency ablation do not alter stem cell mobilization. Europace 10:444-449.
Tselentakis EV, Woodford E, Chandy J, Gaudette GR, Saltman AE. 2006. Inflammation effects on the electrical properties of atrial tissue and inducibility of postoperative atrial fibrillation. J Surg Res 135:68-75.
Tzeis S, Pastromas S, Sikiotis A, Andrikopoulos G. 2016. Cryoablation in persistent atrial fibrillation – a critical appraisal. Neth Heart J 24:498-507.
Weymann A, Ali-Hasan-Al-Saegh S, Sabashnikov A, et al. 2017. Prediction of new-onset and recurrent atrial fibrillation by complete blood count tests: a comprehensive systematic review with meta-analysis. Med Sci Monit Basic Res 23:179-222.
Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. 1991. Probability of stroke: a risk profile from the Framingham study. Stroke 22:312-318.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).